Platteau P, Gabbe M, Famelos M, Kovacs G, Healy D. Should we still advise infertile couples to use (barrier) contraception before IVF down-regulation?
Fertil Steril 2000;
74:655-9. [PMID:
11020502 DOI:
10.1016/s0015-0282(00)01524-7]
[Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
OBJECTIVE
To determine the outcome of spontaneous conceptions in women who received GnRH agonists during mid-luteal phase down-regulation before IVF treatment.
DESIGN
Retrospective analysis of case records and study of the literature.
SETTING
Two university-affiliated reproductive medicine units.
PATIENT(S)
Seventy-three women who conceived spontaneously after starting down-regulation with a GnRH agonist before controlled ovarian hyperstimulation.
INTERVENTION(S)
None.
MAIN OUTCOME MEASURE(S)
Course and clinical outcome of pregnancies.
RESULT(S)
Seventy-four pregnancies occurred in 73 women who received a GnRH agonist. Of these patients, 6 (8%) had a biochemical pregnancy, 6 (8%) had an ectopic pregnancy, 21 (28%) miscarried, and 41 pregnancies resulted in successfully delivered babies; there were 2 cases of congenital abnormalities.
CONCLUSION(S)
These cases, together with other published data, suggest that pregnancy outcome is not adversely affected by exposure to GnRH agonist during luteal-phase down-regulation. A central register of pregnant women who received a GnRH agonist is needed.
Collapse